Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders

Neuropsychopharmacology

Volumn 42, Issue 1, 2017, Pages 193-215

  Haroon, Ebrahim ^a   Miller, Andrew H ^b   Sanacora, Gerard ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTINE; GAMMA INTERFERON; GLUTAMIC ACID; INTERLEUKIN 1BETA; INTERLEUKIN 6; IONOTROPIC RECEPTOR; KYN PROTEIN; METABOTROPIC RECEPTOR; PROTEIN; PURINERGIC P2X7 RECEPTOR; QUINOLINIC ACID; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ARTICLE; ASTROCYTE; ASTROCYTIC DYSFUNCTION; ASTROCYTOSIS; BLOOD BRAIN BARRIER; CELL ACTIVATION; CELL INTERACTION; CIRCUIT INTEGRATION; CLINICAL STUDY; DISEASE SURVEILLANCE; ENZYME INACTIVATION; ENZYME RELEASE; GLIA CELL; GLIOTRANSMISSION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREGULATION; INFLAMMATION; MACROPHAGE; METABOLITE; MICROGLIA; MOLECULAR BIOLOGY; MOOD DISORDER; NERVOUS SYSTEM INFLAMMATION; NEUROPATHY; NEUROTRANSMISSION; NONHUMAN; OLIGODENDROCYTE PROGENITOR; OLIGODENDROGLIA; PHENOTYPIC VARIATION; PRECLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENESCENCE; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; SYNAPTOGENESIS; T LYMPHOCYTE; ANIMAL; GLIA; IMMUNOLOGY; METABOLISM;

ANIMALS; GLUTAMIC ACID; HUMANS; INFLAMMATION; MOOD DISORDERS; NEUROGLIA; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

EID: 84992418546     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2016.199     Document Type: Article

References (286)

1. Abbott NJ, Ronnback L, Hansson E (2006). Astrocyte-endothelial interactions at theblood-brain barrier. Nat Rev Neurosci 7: 41-53.
2. Allam SL, Bouteiller JM, Hu EY, Ambert N, Greget R, Bischoff S, et al. (2015).Synaptic efficacy as a function of ionotropic receptor distribution: acomputational study. PLoS One 10: e0140333.
3. Allam SL, Ghaderi VS, Bouteiller JM, Legendre A, Ambert N, Greget R, et al. (2012). Acomputational model to investigate astrocytic glutamate uptake influence onsynaptic transmission and neuronal spiking. Front Comput Neurosci 6: 70.
4. Arisi GM (2014). Nervous and immune systems signals and connections: cytokinesin hippocampus physiology and pathology. Epilepsy Behav 38: 43-47.
5. Arriza JL, Eliasof S, Kavanaugh MP, Amara SG (1997). Excitatory amino acidtransporter 5, a retinal glutamate transporter coupled to a chloride conductance.Proc Natl Acad Sci USA 94: 4155-4160.
6. Baker DA, McFarland K, Lake RW, Shen H, Tang XC, Toda S, et al. (2003).Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. NatNeurosci 6: 743-749.
7. Banasr M, Chowdhury GM, Terwilliger R, Newton SS, Duman RS, Behar KL, et al.(2010). Glial pathology in an animal model of depression: reversal of stressinducedcellular, metabolic and behavioral deficits by the glutamate-modulatingdrug riluzole. Mol Psychiatry 15: 501-511.
8. Banasr M, Duman RS (2008). Glial loss in the prefrontal cortex is sufficient to inducedepressive-like behaviors. Biol Psychiatry 64: 863-870.
9. Banasr M, Valentine GW, Li XY, Gourley SL, Taylor JR, Duman RS (2007). Chronicunpredictable stress decreases cell proliferation in the cerebral cortex of theadult rat. Biol Psychiatry 62: 496-504.
10. Barley K, Dracheva S, Byne W (2009). Subcortical oligodendrocyte-and astrocyteassociatedgene expression in subjects with schizophrenia, major depression andbipolar disorder. Schizophr Res 112: 54-64.
11. Barres BA (2008). The mystery and magic of glia: a perspective on their roles inhealth and disease. Neuron 60: 430-440.
12. Bartzokis G (2004). Age-related myelin breakdown: a developmental model ofcognitive decline and Alzheimer's disease. Neurobiol Aging 25: 5-18.
13. Baxter PS, Bell KF, Hasel P, Kaindl AM, Fricker M, Thomson D, et al. (2015). SynapticNMDA receptor activity is coupled to the transcriptional control of theglutathione system. Nat Commun 6: 6761.
14. Beattie EC, Stellwagen D, Morishita W, Bresnahan JC, Ha BK, Von Zastrow M, et al.(2002). Control of synaptic strength by glial TNFalpha. Science 295:2282-2285
15. Bechtholt-Gompf AJ, Walther HV, Adams MA, Carlezon WA Jr, Ongur D, Cohen BM(2010). Blockade of astrocytic glutamate uptake in rats induces signs ofanhedonia and impaired spatial memory. Neuropsychopharmacology 35:2049-2059.
16. Bergles DE, Jahr CE (1997). Synaptic activation of glutamate transporters inhippocampal astrocytes. Neuron 19: 1297-1308.
17. Bernard R, Kerman IA, Thompson RC, Jones EG, Bunney WE, Barchas JD, et al.(2011). Altered expression of glutamate signaling, growth factor, and glia genes inthe locus coeruleus of patients with major depression. Mol Psychiatry 16:634-646.
18. Bezzi P, Domercq M, Brambilla L, Galli R, Schols D, De Clercq E, et al. (2001).CXCR4-activated astrocyte glutamate release via TNFalpha: amplification bymicroglia triggers neurotoxicity. Nat Neurosci 4: 702-710.
19. Birey F, Kloc M, Chavali M, Hussein I, Wilson M, Christoffel DJ, et al. (2015). Geneticand stress-induced loss of NG2 glia triggers emergence of depressive-likebehaviors through reduced secretion of FGF2. Neuron 88: 941-956.
20. Bowley MP, Drevets WC, Ongur D, Price JL (2002). Low glial numbers in theamygdala in major depressive disorder. Biol Psychiatry 52: 404-412.
21. Brand A, Richter-Landsberg C, Leibfritz D (1993). Multinuclear NMRstudies on the energy metabolism of glial and neuronal cells. Dev Neurosci 15:289-298.
22. Braun K, Antemano R, Helmeke C, Buchner M, Poeggel G (2009). Juvenileseparation stress induces rapid region-and layer-specific changes in S100ssandglial fibrillary acidic protein-immunoreactivity in astrocytes of the rodent medialprefrontal cortex. Neuroscience 160: 629-638.
23. Brites D, Fernandes A (2015). Neuroinflammation and depression: microgliaactivation, extracellular microvesicles and microRNA dysregulation. Front CellNeurosci 9: 476.
24. Brothers HM, Bardou I, Hopp SC, Kaercher RM, Corona AW, Fenn AM, et al. (2013).Riluzole partially rescues age-associated, but not LPS-induced, loss of glutamatetransporters and spatial memory. J Neuroimmune Pharmacol 8: 1098-1105.
25. Brundin L, Erhardt S, Bryleva EY, Achtyes ED, Postolache TT (2015). The role ofinflammation in suicidal behaviour. Acta Psychiatr Scand 132: 192-203.
26. Bushong EA, Martone ME, Jones YZ, Ellisman MH (2002). Protoplasmic astrocytesin CA1 stratum radiatum occupy separate anatomical domains. J Neurosci 22:183-192.
27. Camacho A, Massieu L (2006). Role of glutamate transporters in the clearance andrelease of glutamate during ischemia and its relation to neuronal death. Arch MedRes 37: 11-18.
28. Capuron L, Neurauter G, Musselman DL, Lawson DH, Nemeroff CB, Fuchs D, et al.(2003). Interferon-alpha-induced changes in tryptophan metabolism. Relationshipto depression and paroxetine treatment. Biol Psychiatry 54: 906-914.
29. Chen X, Errangi B, Li L, Glasser MF, Westlye LT, Fjell AM, et al. (2013). Brain aging inhumans, chimpanzees (Pan troglodytes), and rhesus macaques (Macacamulatta): magnetic resonance imaging studies of macro-and microstructuralchanges. Neurobiol Aging 34: 2248-2260.
30. Cheng B, Christakos S, Mattson MP (1994). Tumor necrosis factors protect neuronsagainst metabolic-excitotoxic insults and promote maintenance of calciumhomeostasis. Neuron 12: 139-153.
31. Chiarugi A, Calvani M, Meli E, Traggiai E, Moroni F (2001a). Synthesis and release ofneurotoxic kynurenine metabolites by human monocyte-derived macrophages. JNeuroimmunol 120: 190-198.
32. Chiarugi A, Meli E, Moroni F (2001b). Similarities and differences in the neuronaldeath processes activated by 3OH-kynurenine and quinolinic acid. J Neurochem77: 1310-1318.
33. Choquet D, Triller A (2013). The dynamic synapse. Neuron 80: 691-703.
34. Chung WS, Clarke LE, Wang GX, Stafford BK, Sher A, Chakraborty C, et al. (2013).Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways.Nature 504: 394-400.
35. Conradt M, Stoffel W (1997). Inhibition of the high-affinity brain glutamate transporterGLAST-1 via direct phosphorylation. J Neurochem 68: 1244-1251.
36. Cotter D, Landau S, Beasley C, Stevenson R, Chana G, MacMillan L, et al. (2002). Thedensity and spatial distribution of GABAergic neurons, labelled using calciumbinding proteins, in the anterior cingulate cortex in major depressive disorder,bipolar disorder, and schizophrenia. Biol Psychiatry 51: 377-386.
37. Cotter DR, Pariante CM, Everall IP (2001). Glial cell abnormalities in major psychiatricdisorders: the evidence and implications. Brain Res Bull 55: 585-595.
38. Czeh B, Simon M, Schmelting B, Hiemke C, Fuchs E (2006). Astroglial plasticity inthe hippocampus is affected by chronic psychosocial stress and concomitantfluoxetine treatment. Neuropsychopharmacology 31: 1616-1626.
39. D'Mello C, Le T, Swain MG (2009). Cerebral microglia recruit monocytes into thebrain in response to tumor necrosis factoralpha signaling during peripheral organinflammation. J Neurosci 29: 2089-2102.
40. Danbolt NC (2001). Glutamate uptake. Prog Neurobiol 65: 1-105.
41. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW (2008). Frominflammation to sickness and depression: when the immune system subjugatesthe brain. Nat Rev Neurosci 9: 46-56.
42. Dantzer R, O'Connor JC, Lawson MA, Kelley KW (2011). Inflammation-associateddepression: from serotonin to kynurenine. Psychoneuroendocrinology 36:426-436.
43. Dantzer R, Walker AK (2014). Is there a role for glutamate-mediated excitotoxicity ininflammation-induced depression? J Neural Transm 121: 925-932.
44. De Pitta M, Brunel N (2016). Modulation of synaptic plasticity by glutamatergicgliotransmission: a modeling study. Neural Plast 2016: 7607924.
45. de Rivero Vaccari JP, Brand F 3rd, Adamczak S, Lee SW, Perez-Barcena J, WangMY, et al. (2016a). Exosome-mediated inflammasome signaling after centralnervous system injury. J Neurochem 136(Suppl 1): 39-48.
46. de Rivero Vaccari JP, Dietrich WD, Keane RW (2014). Activation and regulation ofcellular inflammasomes: gaps in our knowledge for central nervous system injury.J Cereb Blood Flow Metab 34: 369-375.
47. de Rivero Vaccari JP, Dietrich WD, Keane RW (2016b). Therapeuticstargeting the inflammasome after central nervous system injury. Transl Res 167:35-45.
48. Dilger RN, Johnson RW (2008). Aging, microglial cell priming, and the discordantcentral inflammatory response to signals from the peripheral immune system.J Leukoc Biol 84: 932-939.
49. Dimou L, Gallo V (2015). NG2-glia and their functions in the central nervous system.Glia 63: 1429-1451.
50. Domercq M, Sanchez-Gomez MV, Sherwin C, Etxebarria E, Fern R, Matute C(2007). System xc-and glutamate transporter inhibition mediates microglialtoxicity to oligodendrocytes. J Immunol 178: 6549-6556.
51. Dorsett CR, McGuire JL, DePasquale EA, Gardner AE, Floyd CL, McCullumsmith RE(2016). Glutamate neurotransmission in rodent models of traumatic brain injury.J Neurotrauma (e-pub ahead of print; doi:10.1089/neu.2015.4373).
52. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. (2010). A metaanalysisof cytokines in major depression. Biol Psychiatry 67: 446-457.
53. Duman RS (2014). Pathophysiology of depression and innovative treatments:remodeling glutamatergic synaptic connections. Dialogues Clin Neurosci 16:11-27.
54. Duman RS, Aghajanian GK, Sanacora G, Krystal JH (2016). Synaptic plasticity anddepression: new insights from stress and rapid-acting antidepressants. Nat Med22: 238-249.
55. Duman RS, Voleti B (2012). Signaling pathways underlying the pathophysiology andtreatment of depression: novel mechanisms for rapid-acting agents. TrendsNeurosci 35: 47-56.
56. Durieux AM, Fernandes C, Murphy D, Labouesse MA, Giovanoli S, Meyer U, et al.(2015). Targeting glia with N-acetylcysteine modulates brain glutamate andbehaviors relevant to neurodevelopmental disorders in C57BL/6J mice. FrontBehav Neurosci 9: 343.
57. Edgar N, Sibille E (2012). A putative functional role for oligodendrocytes in moodregulation. Transl Psychiatry 2: e109
58. Eggen BJ, Raj D, Hanisch UK, Boddeke HW (2013). Microglial phenotype andadaptation. J Neuroimmune Pharmacol 8: 807-823.
59. Ellwardt E, Walsh JT, Kipnis J, Zipp F (2016). Understanding the role of T cells inCNS homeostasis. Trends Immunol 37: 154-165.
60. Erhardt S, Lim CK, Linderholm KR, Janelidze S, Lindqvist D, Samuelsson M, et al.(2013). Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology38: 743-752.
61. Ernst C, Deleva V, Deng X, Sequeira A, Pomarenski A, Klempan T, et al. (2009).Alternative splicing, methylation state, and expression profile of tropomyosinrelatedkinase B in the frontal cortex of suicide completers. Arch Gen Psychiatry66: 22-32.
62. Estes ML, McAllister AK (2015). Immune mediators in the brain and peripheraltissues in autism spectrum disorder. Nat Rev Neurosci 16: 469-486.
63. Evonuk KS, Baker BJ, Doyle RE, Moseley CE, Sestero CM, Johnston BP, et al.(2015). Inhibition of system Xc(-) transporter attenuates autoimmune inflammatorydemyelination. J Immunol 195: 450-463.
64. Farina C, Aloisi F, Meinl E (2007). Astrocytes are active players in cerebral innateimmunity. Trends Immunol 28: 138-145.
65. Farina C, Krumbholz M, Giese T, Hartmann G, Aloisi F, Meinl E (2005). Preferentialexpression and function of Toll-like receptor 3 in human astrocytes. JNeuroimmunol 159: 12-19.
66. Felger JC, Li Z, Haroon E, Woolwine BJ, Jung MY, Hu X, et al. (2016). Inflammation isassociated with decreased functional connectivity within corticostriatal rewardcircuitry in depression. Mol Psychiatry 21: 1358-1365.
67. Fenn AM, Gensel JC, Huang Y, Popovich PG, Lifshitz J, Godbout JP (2014).Immune activation promotes depression 1 month after diffuse brain injury: a rolefor primed microglia. Biol Psychiatry 76: 575-584.
68. Ferenczi EA, Zalocusky KA, Liston C, Grosenick L, Warden MR, Amatya D, et al.(2016). Prefrontal cortical regulation of brainwide circuit dynamics and rewardrelatedbehavior. Science 351: 9698
69. Figiel I, Dzwonek K (2007). TNFalpha and TNF receptor 1 expression in the mixedneuronal-glial cultures of hippocampal dentate gyrus exposed to glutamate ortrimethyltin. Brain Res 1131: 17-28.
70. Figiel M, Allritz C, Lehmann C, Engele J (2007). Gap junctional control of glialglutamate transporter expression. Mol Cell Neurosci 35: 130-137.
71. Figuera-Losada M, Rojas C, Slusher BS (2014). Inhibition of microgliaactivation as a phenotypic assay in early drug discovery. J Biomol Screen 19:17-31.
72. Fischer R, Wajant H, Kontermann R, Pfizenmaier K, Maier O (2014). Astrocytespecificactivation of TNFR2 promotes oligodendrocyte maturation by secretion ofleukemia inhibitory factor. Glia 62: 272-283.
73. Fontana A, Fierz W, Wekerle H (1984). Astrocytes present myelin basic protein toencephalitogenic T-cell lines. Nature 307: 273-276.
74. Friedman H, Klein T, Specter S, Newton C, Nowotny A (1990). Immunoadjuvanticityof endotoxins and nontoxic derivatives for normal and leukemic immunocytes.Adv Exp Med Biol 256: 525-535.
75. Gamboa C, Ortega A (2002). Insulin-like growth factor-1 increases activity andsurface levels of the GLAST subtype of glutamate transporter. Neurochem Int 40:397-403.
76. Ganor Y, Besser M, Ben-Zakay N, Unger T, Levite M (2003). Human T cells expressa functional ionotropic glutamate receptor GluR3, and glutamate by itself triggersintegrin-mediated adhesion to laminin and fibronectin and chemotactic migration.J Immunol 170: 4362-4372
77. Garg SK, Banerjee R, Kipnis J (2008). Neuroprotective immunity: T cell-derivedglutamate endows astrocytes with a neuroprotective phenotype. J Immunol 180:3866-3873.
78. Garg SK, Kipnis J, Banerjee R (2009). IFN-gamma and IL-4 differentially shapemetabolic responses and neuroprotective phenotype of astrocytes. J Neurochem108: 1155-1166.
79. Gautier HO, Evans KA, Volbracht K, James R, Sitnikov S, Lundgaard I, et al. (2015).Neuronal activity regulates remyelination via glutamate signalling to oligodendrocyteprogenitors. Nat Commun 6: 8518.
80. Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, et al. (2010). Fatemapping analysis reveals that adult microglia derive from primitive macrophages.Science 330: 841-845.
81. Giovanoli S, Weber-Stadlbauer U, Schedlowski M, Meyer U, Engler H (2016).Prenatal immune activation causes hippocampal synaptic deficits in the absenceof overt microglia anomalies. Brain Behav Immun 55: 25-38.
82. Godbout JP, Johnson RW (2009). Age and neuroinflammation: a lifetime ofpsychoneuroimmune consequences. Immunol Allergy Clin North Am 29:321-337.
83. Godbout JP, Moreau M, Lestage J, Chen J, Sparkman NL, O'Connor J, et al. (2008).Aging exacerbates depressive-like behavior in mice in response to activation ofthe peripheral innate immune system. Neuropsychopharmacology 33:2341-2351.
84. Goldsmith DR, Rapaport MH, Miller BJ (2016). A meta-analysis of blood cytokinenetwork alterations in psychiatric patients: comparisons between schizophrenia,bipolar disorder and depression. Mol Psychiatry (e-pub ahead of print;doi:10.1038/mp.2016.3).
85. Gourley SL, Espitia JW, Sanacora G, Taylor JR (2012). Antidepressant-likeproperties of oral riluzole and utility of incentive disengagement models ofdepression in mice. Psychopharmacology 219: 805-814.
86. Graeber MB, Streit WJ (2010). Microglia: biology and pathology. Acta Neuropathol119: 89-105.
87. Gras G, Samah B, Hubert A, Leone C, Porcheray F, Rimaniol AC (2012). EAATexpression by macrophages and microglia: still more questions than answers.Amino Acids 42: 221-229.
88. Guidetti P, Schwarcz R (1999). 3-Hydroxykynurenine potentiates quinolinate but notNMDA toxicity in the rat striatum. Eur J Neurosci 11: 3857-3863.
89. Guillemin GJ (2012). Quinolinic acid, the inescapable neurotoxin. FEBS J 279:1356-1365
90. Guyon A (2014). CXCL12 chemokine and its receptors as major players in theinteractions between immune and nervous systems. Front Cell Neurosci 8: 65.
91. Hamidi M, Drevets WC, Price JL (2004). Glial reduction in amygdalain major depressive disorder is due to oligodendrocytes. Biol Psychiatry 55:563-569.
92. Hannestad J, DellaGioia N, Gallezot JD, Lim K, Nabulsi N, Esterlis I, et al. (2013). Theneuroinflammation marker translocator protein is not elevated in individuals withmild-to-moderate depression: a [(1)(1)C]PBR28 PET study. Brain Behav Immun33: 131-138.
93. Hardingham GE (2009). Coupling of the NMDA receptor to neuroprotective andneurodestructive events. Biochem Soc Trans 37(Pt 6): 1147-1160.
94. Hardingham GE, Bading H (2010). Synaptic vs extrasynaptic NMDA receptorsignalling: implications for neurodegenerative disorders. Nat Rev Neurosci 11:682-696
95. Hardingham GE, Fukunaga Y, Bading H (2002). Extrasynaptic NMDARs opposesynaptic NMDARs by triggering CREB shut-off and cell death pathways. NatNeurosci 5: 405-414.
96. Haroon E, Felger JC, Woolwine BJ, Chen X, Parekh S, Spivey JR, et al. (2015). Agerelatedincreases in basal ganglia glutamate are associated with TNF, reducedmotivation and decreased psychomotor speed during IFN-alpha treatment:preliminary findings. Brain Behav Immun 46: 17-22.
97. Haroon E, Fleischer CC, Felger JC, Chen X, Woolwine BJ, Patel T, et al. (2016).Conceptual convergence: increased inflammation is associated with increasedbasal ganglia glutamate in patients with major depression. Mol Psychiatry 21:1351-1357.
98. Haroon E, Raison CL, Miller AH (2012). Psychoneuroimmunology meets neuropsychopharmacology:translational implications of the impact of inflammation onbehavior. Neuropsychopharmacology 37: 137-162.
99. Haroon E, Watari K, Thomas A, Ajilore O, Mintz J, Elderkin-Thompson V, et al. (2009).Prefrontal myo-inositol concentration and visuospatial functioning among diabeticdepressed patients. Psychiatry Res 171: 10-19.
100. Haroon E, Woolwine BJ, Chen X, Pace TW, Parekh S, Spivey JR, et al. (2014). IFNalpha-induced cortical and subcortical glutamate changes assessed by magneticresonance spectroscopy. Neuropsychopharmacology 39: 1777-1785
101. Hashimoto K (2015). Inflammatory biomarkers as differential predictors ofantidepressant response. Int J Mol Sci 16: 7796-7801.
102. Haydon PG, Carmignoto G (2006). Astrocyte control of synaptic transmission andneurovascular coupling. Physiol Rev 86: 1009-1031.
103. Heinisch S, Kirby LG (2010). SDF-1alpha/CXCL12 enhances GABA and glutamatesynaptic activity at serotonin neurons in the rat dorsal raphe nucleus.Neuropharmacology 58: 501-514.
104. Helms HC, Madelung R, Waagepetersen HS, Nielsen CU, Brodin B (2012). In vitroevidence for the brain glutamate efflux hypothesis: brain endothelial cellscocultured with astrocytes display a polarized brain-to-blood transport ofglutamate. Glia 60: 882-893.
105. Howren MB, Lamkin DM, Suls J (2009). Associations of depression with C-reactiveprotein, IL-1, and IL-6: a meta-analysis. Psychosom Med 71: 171-186.
106. Hsuchou H, Pan W, Barnes MJ, Kastin AJ (2009). Leptin receptor mRNA in rat brainastrocytes. Peptides 30: 2275-2280.
107. Hu S, Sheng WS, Ehrlich LC, Peterson PK, Chao CC (2000). Cytokine effects onglutamate uptake by human astrocytes. Neuroimmunomodulation 7: 153-159.
108. Ida T, Hara M, Nakamura Y, Kozaki S, Tsunoda S, Ihara H (2008). Cytokine-inducedenhancement of calcium-dependent glutamate release from astrocytes mediatedby nitric oxide. Neurosci Lett 432: 232-236.
109. Iliff JJ, Nedergaard M (2013). Is there a cerebral lymphatic system? Stroke 44(6Suppl 1): S93-S95.
110. Innocenti B, Parpura V, Haydon PG (2000). Imaging extracellular waves of glutamateduring calcium signaling in cultured astrocytes. J Neurosci 20: 1800-1808.
111. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al. (2010). Researchdomain criteria (RDoC): toward a new classification framework for research onmental disorders. Am J Psychiatry 167: 748-751.
112. Iori V, Frigerio F, Vezzani A (2016). Modulation of neuronal excitability by immunemediators in epilepsy. Curr Opin Pharmacol 26: 118-123.
113. Ishibashi T, Dakin KA, Stevens B, Lee PR, Kozlov SV, Stewart CL, et al. (2006). Astrocytespromote myelination in response to electrical impulses. Neuron 49: 823-832.
114. Iwata M, Ota KT, Duman RS (2013). The inflammasome: pathways linking psychologicalstress, depression, and systemic illnesses. Brain Behav Immun 31: 105-114.
115. Iwata M, Ota KT, Li XY, Sakaue F, Li N, Dutheil S, et al. (2016). Psychological stressactivates the inflammasome via release of Adenosine Triphosphate andstimulation of the purinergic type 2X7 receptor. Biol Psychiatry 80: 12-22.
116. Jackman NA, Uliasz TF, Hewett JA, Hewett SJ (2010). Regulation of system x(c)(-)activity and expression in astrocytes by interleukin-1beta: implications for hypoxicneuronal injury. Glia 58: 1806-1815.
117. Jaso BA, Niciu MJ, Iadarola ND, Lally N, Richards EM, Park M, et al. (2016).Therapeutic modulation of glutamate receptors in major depressive disorder. CurrNeuropharmacol. (e-pub ahead of print; pii:CN-EPUB-74491)
118. Jebelli J, Su W, Hopkins S, Pocock J, Garden GA (2015). Glia: guardians, gluttons,or guides for the maintenance of neuronal connectivity? Ann NY Acad Sci 1351:1-10.
119. Johnstone M, Gearing AJ, Miller KM (1999). A central role for astrocytes in theinflammatory response to beta-amyloid; chemokines, cytokines and reactiveoxygen species are produced. J Neuroimmunol 93: 182-193.
120. Kalandadze A, Wu Y, Fournier K, Robinson MB (2004). Identification of motifsinvolved in endoplasmic reticulum retention-forward trafficking of the GLT-1subtype of glutamate transporter. J Neurosci 24: 5183-5192.
121. Karpuk N, Burkovetskaya M, Kielian T (2012). Neuroinflammation alters voltagedependentconductance in striatal astrocytes. J Neurophysiol 108: 112-123.
122. Kettenmann H, Hanisch UK, Noda M, Verkhratsky A (2011). Physiology of microglia.Physiol Rev 91: 461-553
123. Kettenmann H, Ransom BR (2012). Neuroglia. Oxford University Press: New York,NY.
124. Khakh BS, Sofroniew MV (2015). Diversity of astrocyte functions and phenotypes inneural circuits. Nat Neurosci 18: 942-952.
125. Kielian T, Bearden ED, Baldwin AC, Esen N (2004). IL-1 and TNF-alpha play a pivotalrole in the host immune response in a mouse model of Staphylococcus aureusinducedexperimental brain abscess. J Neuropathol Exp Neurol 63: 381-396.
126. Kielian T, Esen N (2004). Effects of neuroinflammation on glia-glia gap junctionalintercellular communication: a perspective. Neurochem Int 45: 429-436.
127. Kigerl KA, Ankeny DP, Garg SK, Wei P, Guan Z, Lai W, et al. (2012). System x(c)(-)regulates microglia and macrophage glutamate excitotoxicity in vivo. Exp Neurol233: 333-341.
128. Kim H, McGrath BM, Silverstone PH (2005). A review of the possible relevance ofinositol and the phosphatidylinositol second messenger system (PI-cycle) topsychiatric disorders-focus on magnetic resonance spectroscopy (MRS)studies. Hum Psychopharmacol 20: 309-326.
129. Kimelberg HK, Nedergaard M (2010). Functions of astrocytes and their potential astherapeutic targets. Neurotherapeutics 7: 338-353.
130. Kipnis J, Gadani S, Derecki NC (2012). Pro-cognitive properties of T cells. Nat RevImmunol 12: 663-669.
131. Korn T, Magnus T, Jung S (2005). Autoantigen specific T cells inhibit glutamateuptake in astrocytes by decreasing expression of astrocytic glutamate transporterGLAST: a mechanism mediated by tumor necrosis factor-alpha. FASEB J 19:1878-1880.
132. Kumar A, Stoica BA, Sabirzhanov B, Burns MP, Faden AI, Loane DJ (2013).Traumatic brain injury in aged animals increases lesion size and chronically altersmicroglial/macrophage classical and alternative activation states. Neurobiol Aging34: 1397-1411.
133. Le Y, Zhou Y, Iribarren P, Wang J (2004). Chemokines and chemokine receptors:their manifold roles in homeostasis and disease. Cell Mol Immunol 1: 95-104.
134. Leibowitz A, Boyko M, Shapira Y, Zlotnik A (2012). Blood glutamate scavenging:insight into neuroprotection. Int J Mol Sci 13: 10041-10066.
135. Levite M (2014). Glutamate receptor antibodies in neurological diseases. J NeuralTransm (Vienna) 121: 1029-1075.
136. Levy LM, Warr O, Attwell D (1998). Stoichiometry of the glial glutamate transporterGLT-1 expressed inducibly in a Chinese hamster ovary cell line selected for lowendogenous Na+-dependent glutamate uptake. J Neurosci 18: 9620-9628.
137. Lewerenz J, Hewett SJ, Huang Y, Lambros M, Gout PW, Kalivas PW, et al. (2013).The cystine/glutamate antiporter system x(c)(-) in health and disease: frommolecular mechanisms to novel therapeutic opportunities. Antioxid Redox Signal18: 522-555.
138. Lewerenz J, Maher P (2015). Chronic glutamate toxicity in neurodegenerativediseases-what is the evidence? Front Neurosci 9: 469.
139. Li X, Wallin C, Weber SG, Sandberg M (1999). Net efflux of cysteine, glutathione andrelated metabolites from rat hippocampal slices during oxygen/glucose deprivation:dependence on gamma-glutamyl transpeptidase. Brain Res 815: 81-88.
140. Liberto CM, Albrecht PJ, Herx LM, Yong VW, Levison SW (2004). Pro-regenerativeproperties of cytokine-activated astrocytes. J Neurochem 89: 1092-1100.
141. Liddelow S, Barres B (2015). SnapShot: astrocytes in health and disease. Cell 162:1170-1170 e1171.
142. Longuemare MC, Swanson RA (1995). Excitatory amino acid release fromastrocytes during energy failure by reversal of sodium-dependent uptake. JNeurosci Res 40: 379-386.
143. Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et al. (2015).Structural and functional features of central nervous system lymphatic vessels.Nature 523: 337-341.
144. Ma TM, Paul BD, Fu C, Hu S, Zhu H, Blackshaw S, et al. (2014). Serine racemaseregulated by binding to stargazin and PSD-95: potential N-methyl-D-aspartatealpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (NMDA-AMPA) glutamateneurotransmission cross-talk. J Biol Chem 289: 29631-29641.
145. Machado-Vieira R, Gold PW, Luckenbaugh DA, Ballard ED, Richards EM, Henter IDet al (2016). The role of adipokines in the rapid antidepressant effects of ketamine.Mol Psychiatry in press).
146. Machado-Vieira R, Salvadore G, Diazgranados N, Zarate CA Jr (2009). Ketamineand the next generation of antidepressants with a rapid onset of action.Pharmacol Ther 123: 143-150.
147. Malarkey EB, Parpura V (2008). Mechanisms of glutamate release from astrocytes.Neurochem Int 52: 142-154.
148. Marz P, Heese K, Dimitriades-Schmutz B, Rose-John S, Otten U (1999). Role ofinterleukin-6 and soluble IL-6 receptor in region-specific induction of astrocyticdifferentiation and neurotrophin expression. Glia 26: 191-200.
149. Massie A, Boillee S, Hewett S, Knackstedt L, Lewerenz J (2015). Main path andbyways: non-vesicular glutamate release by system xc(-) as an important modifierof glutamatergic neurotransmission. J Neurochem 135: 1062-1079.
150. Matcovitch-Natan O, Winter DR, Giladi A, Vargas Aguilar S, Spinrad A, Sarrazin Set al (2016). Microglia development follows a stepwise program to regulate brainhomeostasis. Science. (e-pub ahead of print;doi:10.1126/science.aad8670)
151. Mateo C, Avermann M, Gentet LJ, Zhang F, Deisseroth K, Petersen CC (2011). Invivo optogenetic stimulation of neocortical excitatory neurons drives brain-statedependentinhibition. Curr Biol 21: 1593-1602.
152. Mathew S, Fava M, Guerguieva R, Sanacora G(eds) (2015). A Randomized Placebo-Controlled Adjunctive Trial of Riluzole in Treatment-Resistant Major DepressiveDisorder-NCT01204918-Efficacy and Tolerability of Riluzole in TreatmentResistant Depression. ASCP Annual Meeting (NCDEU)
153. Miami, FL, USA.Matute C (2006). Oligodendrocyte NMDA receptors: a novel therapeutic target.Trends Mol Med 12: 289-292.
154. Matute C, Domercq M, Sanchez-Gomez MV (2006). Glutamate-mediated glial injury:mechanisms and clinical importance. Glia 53: 212-224.
155. McCullumsmith RE, Sanacora G (2015). Regulation of extrasynaptic glutamate levelsas a pathophysiological mechanism in disorders of motivation and addiction.Neuropsychopharmacology 40: 254-255.
156. McEwen BS, Nasca C, Gray JD (2016). Stress effects on neuronal structure:hippocampus, amygdala, and prefrontal cortex. Neuropsychopharmacology 41:3-23.
157. Medina A, Watson SJ, Bunney W Jr, Myers RM, Schatzberg A, Barchas J, et al.(2016). Evidence for alterations of the glial syncytial function in major depressivedisorder. J Psychiatr Res 72: 15-21.
158. Merzenich MM, Van Vleet TM, Nahum M (2014). Brain plasticity-based therapeutics.Front Hum Neurosci 8: 385.
159. Mesci P, Zaidi S, Lobsiger CS, Millecamps S, Escartin C, Seilhean D, et al. (2015).System xC-is a mediator of microglial function and its deletion slows symptoms inamyotrophic lateral sclerosis mice. Brain 138(Pt 1): 53-68.
160. Miguel-Hidalgo JJ, Wilson BA, Hussain S, Meshram A, Rajkowska G, StockmeierCA (2014). Reduced connexin 43 immunolabeling in the orbitofrontal cortex inalcohol dependence and depression. J Psychiatr Res 55: 101-109.
161. Miller AH, Raison CL (2016). The role of inflammation in depression: fromevolutionary imperative to modern treatment target. Nat Rev Immunol 16:22-34.
162. Miller KR, Streit WJ (2007). The effects of aging, injury and disease on microglialfunction: a case for cellular senescence. Neuron Glia Biol 3: 245-253.
163. Milton ID, Banner SJ, Ince PG, Piggott NH, Fray AE, Thatcher N, et al. (1997).Expression of the glial glutamate transporter EAAT2 in the human CNS: animmunohistochemical study. Brain Res Mol Brain Res 52: 17-31.
164. Mineur YS, Picciotto MR, Sanacora G (2007). Antidepressant-like effects ofceftriaxone in male C57BL/6J mice. Biol Psychiatry 61: 250-252.
165. Mizuno T, Zhang G, Takeuchi H, Kawanokuchi J, Wang J, Sonobe Y, et al. (2008).Interferon-gamma directly induces neurotoxicity through a neuron specific,calcium-permeable complex of IFN-gamma receptor and AMPA GluR1 receptor.FASEB J 22: 1797-1806.
166. Moylan S, Maes M, Wray NR, Berk M (2013). The neuroprogressive nature of majordepressive disorder: pathways to disease evolution and resistance, andtherapeutic implications. Mol Psychiatry 18: 595-606.
167. Myint AM, Kim YK, Verkerk R, Scharpe S, Steinbusch H, Leonard B (2007).Kynurenine pathway in major depression: evidence of impaired neuroprotection. JAffect Disord 98: 143-151.
168. Nagy C, Suderman M, Yang J, Szyf M, Mechawar N, Ernst C, et al. (2015). Astrocyticabnormalities and global DNA methylation patterns in depression and suicide. MolPsychiatry 20: 320-328.
169. Najjar S, Pearlman DM, Alper K, Najjar A, Devinsky O (2013). Neuroinflammation andpsychiatric illness. J Neuroinflammation 10: 43.
170. Nakagawa T, Otsubo Y, Yatani Y, Shirakawa H, Kaneko S (2008). Mechanisms ofsubstrate transport-induced clustering of a glial glutamate transporter GLT-1 inastroglial-neuronal cultures. Eur J Neurosci 28: 1719-1730.
171. Nathan C, Cunningham-Bussel A (2013). Beyond oxidative stress: an immunologist'sguide to reactive oxygen species. Nat Rev Immunol 13: 349-361
172. Nedergaard M, Takano T, Hansen AJ (2002). Beyond the role of glutamate as aneurotransmitter. Nat Rev Neurosci 3: 748-755.
173. Niciu MJ, Ionescu DF, Richards EM, Zarate CA Jr (2014a). Glutamate and itsreceptors in the pathophysiology and treatment of major depressive disorder. JNeural Transm 121: 907-924.
174. Niciu MJ, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, Ballard EDet al (2014b). Riluzole likely lacks antidepressant efficacy in ketamine nonresponders.J Psychiatr Res 58: 197-199.
175. Nimmerjahn A, Kirchhoff F, Helmchen F (2005). Resting microglial cellsare highly dynamic surveillants of brain parenchyma in vivo. Science 308:1314-1318.
176. Noda M, Nakanishi H, Nabekura J, Akaike N (2000). AMPA-kainate subtypes ofglutamate receptor in rat cerebral microglia. J Neurosci 20: 251-258.
177. Norden DM, Godbout JP (2013). Review: microglia of the aged brain:primed to be activated and resistant to regulation. Neuropathol Appl Neurobiol39: 19-34.
178. Norden DM, Muccigrosso MM, Godbout JP (2015a). Microglial priming andenhanced reactivity to secondary insult in aging, and traumatic CNS injury, andneurodegenerative disease. Neuropharmacology 96(Pt A): 29-41.
179. Norden DM, Trojanowski PJ, Walker FR, Godbout JP (2016). Insensitivity ofastrocytes to interleukin 10 signaling following peripheral immune challengeresults in prolonged microglial activation in the aged brain. Neurobiol Aging 44:22-41.
180. Norden DM, Trojanowski PT, Walker FR, Godbout JP (2015b). Age-relatedimpairments in the dynamic regulation of active microglia by astrocytes. BrainBehav Immun 49: e16-e17.
181. Ohgoh M, Hanada T, Smith T, Hashimoto T, Ueno M, Yamanishi Y, et al. (2002).Altered expression of glutamate transporters in experimental autoimmuneencephalomyelitis. J Neuroimmunol 125: 170-178.
182. Oka A, Belliveau MJ, Rosenberg PA, Volpe JJ (1993). Vulnerability of oligodendrogliato glutamate: pharmacology, mechanisms, and prevention. J Neurosci 13:1441-1453.
183. Olmos G, Llado J (2014). Tumor necrosis factor alpha: a link betweenneuroinflammation and excitotoxicity. Mediators Inflamm 2014: 861231.
184. Ongur D, Bechtholt AJ, Carlezon WA Jr, Cohen BM (2014). Glial abnormalities inmood disorders. Harv Rev Psychiatry 22: 334-337.
185. Ongur D, Drevets WC, Price JL (1998). Glial reduction in the subgenual prefrontalcortex in mood disorders. Proc Natl Acad Sci USA 95: 13290-13295.
186. MDD and BD.Oxenkrug G (2011). Interferon-gamma-inducible inflammation:contribution to aging and aging-associated psychiatric disorders. Aging Dis 2:474-486.
187. Oxenkrug GF (2010). Metabolic syndrome, age-associated neuroendocrinedisorders, and dysregulation of tryptophan-kynurenine metabolism. Ann NY AcadSci 1199: 1-14.
188. Pan W, Hsuchou H, Jayaram B, Khan RS, Huang EY, Wu X, et al. (2012). Leptinaction on nonneuronal cells in the CNS: potential clinical applications. Ann NYAcad Sci 1264: 64-71.
189. Parpura V, Verkhratsky A (2013). Astroglial amino acid-based transmitter receptors.Amino Acids 44: 1151-1158.
190. Parri HR, Gould TM, Crunelli V (2001). Spontaneous astrocytic Ca2+ oscillationsin situ drive NMDAR-mediated neuronal excitation. Nat Neurosci 4: 803-812.
191. Persson M, Brantefjord M, Hansson E, Ronnback L (2005). Lipopolysaccharideincreases microglial GLT-1 expression and glutamate uptake capacity in vitro by amechanism dependent on TNF-alpha. Glia 51: 111-120.
192. Petrelli F, Bezzi P (2016). Novel insights into gliotransmitters. Curr Opin Pharmacol26: 138-145
193. Piani D, Fontana A (1994). Involvement of the cystine transport system xc-in themacrophage-induced glutamate-dependent cytotoxicity to neurons. J Immunol152: 3578-3585.
194. Piani D, Frei K, Do KQ, Cuenod M, Fontana A (1991). Murine brain macrophagesinduced NMDA receptor mediated neurotoxicity in vitro by secreting glutamate.Neurosci Lett 133: 159-162.
195. Piers TM, Heales SJ, Pocock JM (2011). Positive allosteric modulation ofmetabotropic glutamate receptor 5 down-regulates fibrinogen-activated microgliaproviding neuronal protection. Neurosci Lett 505: 140-145.
196. Pittenger C, Coric V, Banasr M, Bloch M, Krystal JH, Sanacora G (2008). Riluzole inthe treatment of mood and anxiety disorders. CNS Drugs 22: 761-786.
197. Plitman E, de la Fuente-Sandoval C, Reyes-Madrigal F, Chavez S, Gomez-Cruz G,Leon-Ortiz P, et al. (2016). Elevated myo-inositol, choline, and glutamate levels inthe associative striatum of antipsychotic-naive patients with first-episodepsychosis: a proton magnetic resonance spectroscopy study with implicationsfor glial dysfunction. Schizophr Bull 42: 415-424.
198. Pocock JM, Kettenmann H (2007). Neurotransmitter receptors on microglia. TrendsNeurosci 30: 527-535.
199. Popoli M, Yan Z, McEwen BS, Sanacora G (2012). The stressed synapse: theimpact of stress and glucocorticoids on glutamate transmission. Nat RevNeurosci 13: 22-37.
200. Pribiag H, Stellwagen D (2014). Neuroimmune regulation of homeostatic synapticplasticity. Neuropharmacology 78: 13-22.
201. Pribiag M, Stellwagen D (2013)Neuroimmune modulation of synaptic functionIn:CuiC, Grandison L, Noronha A(eds) Neural-Immune Interations in Brain Functionsand Alcoho-Related Disorders. Springer: New York, NY, USA. pp 65-94.
202. Raison CL, Dantzer R, Kelley KW, Lawson MA, Woolwine BJ, Vogt G, et al. (2010).CSF concentrations of brain tryptophan and kynurenines during immunestimulation with IFN-alpha: relationship to CNS immune responses anddepression. Mol Psychiatry 15: 393-403.
203. Rajkowska G, Mahajan G, Maciag D, Sathyanesan M, Iyo AH, Moulana M, et al.(2015). Oligodendrocyte morphometry and expression of myelin-Related mRNAin ventral prefrontal white matter in major depressive disorder. J Psychiatr Res 65:53-62.
204. Rajkowska G, Miguel-Hidalgo JJ (2007). Gliogenesis and glial pathology indepression. CNS Neurol Disord Drug Targets 6: 219-233.
205. Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY, et al.(1999). Morphometric evidence for neuronal and glial prefrontal cell pathology inmajor depression. Biol Psychiatry 45: 1085-1098.
206. Rajkowska G, Stockmeier CA (2013). Astrocyte pathology in major depressivedisorder: insights from human postmortem brain tissue. Curr Drug Targets 14:1225-1236.
207. Ransohoff RM (2016). A polarizing question: do M1 and M2 microglia exist? NatNeurosci 19: 987-991
208. Regan MR, Huang YH, Kim YS, Dykes-Hoberg MI, Jin L, Watkins AM, et al. (2007).Variations in promoter activity reveal a differential expression and physiology ofglutamate transporters by glia in the developing and mature CNS. J Neurosci 27:6607-6619.
209. Reus GZ, Fries GR, Stertz L, Badawy M, Passos IC, Barichello T, et al. (2015). Therole of inflammation and microglial activation in the pathophysiology of psychiatricdisorders. Neuroscience 300: 141-154.
210. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O (1999). Reference distributionsfor the negative acute-phase proteins, albumin, transferrin, and transthyretin: comparison of a large cohort to the world's literature. J Clin Lab Anal 13:280-286.
211. Rossi D (2015). Astrocyte physiopathology: at the crossroads of intercellularnetworking, inflammation and cell death. Prog Neurobiol 130: 86-120.
212. Rossi DJ, Oshima T, Attwell D (2000). Glutamate release in severe brain ischaemia ismainly by reversed uptake. Nature 403: 316-321.
213. Rothstein JD (1996). Excitotoxicity hypothesis. Neurology 47(4 Suppl 2): S19-S25.
214. Salardini E, Zeinoddini A, Mohammadinejad P, Khodaie-Ardakani MR, Zahraei N,Zeinoddini A, et al. (2016). Riluzole combination therapy for moderate-to-severemajor depressive disorder: a randomized, double-blind, placebo-controlled trial. JPsychiatr Res 75: 24-30.
215. Salminen A, Ojala J, Kaarniranta K, Haapasalo A, Hiltunen M, Soininen H (2011).Astrocytes in the aging brain express characteristics of senescence-associatedsecretory phenotype. Eur J Neurosci 34: 3-11.
216. Sanacora G, Banasr M (2013). From pathophysiology to novel antidepressant drugs:glial contributions to the pathology and treatment of mood disorders. BiolPsychiatry 73: 1172-1179.
217. Sanacora G, Treccani G, Popoli M (2012). Towards a glutamate hypothesis ofdepression: an emerging frontier of neuropsychopharmacology for mooddisorders. Neuropharmacology 62: 63-77.
218. Sandiego CM, Gallezot JD, Pittman B, Nabulsi N, Lim K, Lin SF, et al. (2015). Imagingrobust microglial activation after lipopolysaccharide administration in humanswith PET. Proc Natl Acad Sci USA 112: 12468-12473.
219. Santello M, Bezzi P, Volterra A (2011). TNFalpha controls glutamatergicgliotransmission in the hippocampal dentate gyrus. Neuron 69: 988-1001.
220. Santello M, Volterra A (2012). TNFalpha in synaptic function: switching gears. TrendsNeurosci 35: 638-647.
221. Savitz J, Drevets WC, Smith CM, Victor TA, Wurfel BE, Bellgowan PS, et al. (2015).Putative neuroprotective and neurotoxic kynurenine pathway metabolites areassociated with hippocampal and amygdalar volumes in subjects with majordepressive disorder. Neuropsychopharmacology 40: 463-471.
222. Schafer DP, Stevens B (2015). Microglia function in central nervous systemdevelopment and plasticity. Cold Spring Harb Perspect Biol 7: a020545.
223. Schluter K, Figiel M, Rozyczka J, Engele J (2002). CNS region-specific regulation ofglial glutamate transporter expression. Eur J Neurosci 16: 836-842.
224. Schwarcz R (2004). The kynurenine pathway of tryptophan degradation as adrug target. Curr Opin Pharmacol 4: 12-17.
225. Schwarcz R (2016). Kynurenines and glutamate: multiple links and therapeuticimplications. Adv Pharmacol 76: 13-37
226. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ (2012). Kynurenines in themammalian brain: when physiology meets pathology. Nat Rev Neurosci 13:465-477.
227. Schwarcz R, Pellicciari R (2002). Manipulation of brain kynurenines: glial targets,neuronal effects, and clinical opportunities. J Pharmacol Exp Ther 303: 1-10.
228. Sequeira A, Mamdani F, Ernst C, Vawter MP, Bunney WE, Lebel V, et al. (2009).Global brain gene expression analysis links glutamatergic and GABAergicalterations to suicide and major depression. PLoS One 4: e6585.
229. Setiawan E, Wilson AA, Mizrahi R, Rusjan PM, Miler L, Rajkowska G, et al. (2015).Role of translocator protein density, a marker of neuroinflammation, in the brainduring major depressive episodes. JAMA Psychiatry 72: 268-275.
230. Shan D, Lucas EK, Drummond JB, Haroutunian V, Meador-Woodruff JH,McCullumsmith RE (2013). Abnormal expression of glutamate transporters intemporal lobe areas in elderly patients with schizophrenia. Schizophr Res 144:1-8.
231. Sheng M, Hoogenraad CC (2007). The postsynaptic architecture of excitatorysynapses: a more quantitative view. Annu Rev Biochem 76: 823-847.
232. Shrikant P, Benveniste EN (1996). The central nervous system as an immunocompetentorgan: role of glial cells in antigen presentation. J Immunol 157:1819-1822.
233. Sofroniew MV, Vinters HV (2010). Astrocytes: biology and pathology. ActaNeuropathol 119: 7-35.
234. Soos JM, Morrow J, Ashley TA, Szente BE, Bikoff EK, Zamvil SS (1998). Astrocytesexpress elements of the class II endocytic pathway and process central nervoussystem autoantigen for presentation to encephalitogenic T cells. J Immunol 161:5959-5966.
235. Spranger M, Lindholm D, Bandtlow C, Heumann R, Gnahn H, Naher-Noe M, et al.(1990). Regulation of nerve growth factor (NGF) synthesis in the rat centralnervous system: comparison between the effects of interleukin-1 and variousgrowth factors in astrocyte cultures and in vivo. Eur J Neurosci 2: 69-76.
236. Stone TW, Forrest CM, Darlington LG (2012). Kynurenine pathway inhibition as atherapeutic strategy for neuroprotection. FEBS J 279: 1386-1397.
237. Streit WJ, Xue QS (2013). Microglial senescence. CNS Neurol Disord Drug Targets12: 763-767.
238. Sun JD, Liu Y, Yuan YH, Li J, Chen NH (2012). Gap junction dysfunction in theprefrontal cortex induces depressive-like behaviors in rats. Neuropsychopharmacology37: 1305-1320.
239. Szymocha R, Akaoka H, Dutuit M, Malcus C, Didier-Bazes M, Belin MF, et al. (2000).Human T-cell lymphotropic virus type 1-infected T lymphocytes impair catabolismand uptake of glutamate by astrocytes via Tax-1 and tumor necrosis factor alpha.J Virol 74: 6433-6441.
240. Takahashi JL, Giuliani F, Power C, Imai Y, Yong VW (2003a). Interleukin-1betapromotes oligodendrocyte death through glutamate excitotoxicity. Ann Neurol 53:588-595.
241. Takahashi K, Foster JB, Lin CL (2015). Glutamate transporter EAAT2: regulation,function, and potential as a therapeutic target for neurological and psychiatricdisease. Cell Mol Life Sci 72: 3489-3506.
242. Takahashi T, Svoboda K, Malinow R (2003b). Experience strengthening transmissionby driving AMPA receptors into synapses. Science 299: 1585-1588.
243. Takaki J, Fujimori K, Miura M, Suzuki T, Sekino Y, Sato K (2012). L-glutamatereleased from activated microglia downregulates astrocytic L-glutamate transporterexpression in neuroinflammation: the 'collusion' hypothesis for increasedextracellular L-glutamate concentration in neuroinflammation. J Neuroinflammation9: 275.
244. Takeuchi H, Jin S, Suzuki H, Doi Y, Liang J, Kawanokuchi J, et al. (2008). Blockade ofmicroglial glutamate release protects against ischemic brain injury. Exp Neurol214: 144-146.
245. Takeuchi H, Jin S, Wang J, Zhang G, Kawanokuchi J, Kuno R, et al. (2006). Tumornecrosis factor-alpha induces neurotoxicity via glutamate release from hemichannelsof activated microglia in an autocrine manner. J Biol Chem 281:21362-21368.
246. Takeuchi H, Suzumura A (2014). Gap junctions and hemichannels composed ofconnexins: potential therapeutic targets for neurodegenerative diseases. FrontCell Neurosci 8: 189.
247. Tavares RG, Tasca CI, Santos CE, Alves LB, Porciuncula LO, Emanuelli T, et al.(2002). Quinolinic acid stimulates synaptosomal glutamate release and inhibitsglutamate uptake into astrocytes. Neurochem Int 40: 621-627.
248. Taylor DL, Jones F, Kubota ES, Pocock JM (2005). Stimulation of microglialmetabotropic glutamate receptor mGlu2 triggers tumor necrosis factor alphainducedneurotoxicity in concert with microglial-derived Fas ligand. J Neurosci 25:2952-2964.
249. Tilleux S, Hermans E (2007). Neuroinflammation and regulation of glial glutamateuptake in neurological disorders. J Neurosci Res 85: 2059-2070.
250. Torres-Platas SG, Comeau S, Rachalski A, Bo GD, Cruceanu C, Turecki G, et al.(2014a). Morphometric characterization of microglial phenotypes in humancerebral cortex. J Neuroinflammation 11: 12.
251. Torres-Platas SG, Cruceanu C, Chen GG, Turecki G, Mechawar N (2014b).Evidence for increased microglial priming and macrophage recruitment in thedorsal anterior cingulate white matter of depressed suicides. Brain Behav Immun42: 50-59.
252. Torres-Platas SG, Hercher C, Davoli MA, Maussion G, Labonte B, Turecki G, et al.(2011). Astrocytic hypertrophy in anterior cingulate white matter of depressedsuicides. Neuropsychopharmacology 36: 2650-2658.
253. Town T, Nikolic V, Tan J (2005). The microglial 'activation' continuum: from innate toadaptive responses. J Neuroinflammation 2: 24.
254. Tzingounis AV, Wadiche JI (2007). Glutamate transporters: confining runawayexcitation by shaping synaptic transmission. Nat Rev Neurosci 8: 935-947.
255. Valkanova V, Ebmeier KP, Allan CL (2013). CRP, IL-6 and depression: a systematicreview and meta-analysis of longitudinal studies. J Affect Disord 150: 736-744.
256. Vecsei L, Szalardy L, Fulop F, Toldi J (2013). Kynurenines in the CNS: recentadvances and new questions. Nat Rev Drug Discov 12: 64-82.
257. Vercellino M, Merola A, Piacentino C, Votta B, Capello E, Mancardi GL, et al. (2007).Altered glutamate reuptake in relapsing-remitting and secondary progressivemultiple sclerosis cortex: correlation with microglia infiltration, demyelination, andneuronal and synaptic damage. J Neuropathol Exp Neurol 66: 732-739.
258. Verkharatsky A, Butt A (2013). Glial Physiology and Pathophysiology. Wiley-Blackwell: West Sussex, UK.
259. Verkhratsky A, Nedergaard M, Hertz L (2016). Why are astrocytes important?Neurochem Res 40: 389-401.
260. Verkhratsky A, Rodriguez JJ, Parpura V (2014). Neuroglia in ageing and disease. CellTissue Res 357: 493-503.
261. Verkhratsky A, Steardo L, Parpura V, Montana V (2016). Translational potential ofastrocytes in brain disorders. Prog Neurobiol 144: 188-205.
262. Vezzani A, Viviani B (2015). Neuromodulatory properties of inflammatorycytokines and their impact on neuronal excitability. Neuropharmacology 96(Pt A):70-82.
263. Viviani B, Boraso M (2011). Cytokines and neuronal channels: a molecular basis forage-related decline of neuronal function? Exp Gerontol 46: 199-206.
264. Volterra A, Meldolesi J (2005). Astrocytes, from brain glue to communicationelements: the revolution continues. Nat Rev Neurosci 6: 626-640.
265. Walker AJ, Foley BM, Sutor SL, McGillivray JA, Frye MA, Tye SJ (2015). Peripheralproinflammatory markers associated with ketamine response in a preclinicalmodel of antidepressant-resistance. Behav Brain Res 293: 198-202.
266. Walker AK, Budac DP, Bisulco S, Lee AW, Smith RA, Beenders B, et al. (2013).NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induceddepressive-like behavior in C57BL/6J mice. Neuropsychopharmacology 38:1609-1616.
267. Walsh JG, Muruve DA, Power C (2014a). Inflammasomes in the CNS. Nat RevNeurosci 15: 84-97.
268. Walsh JT, Watson N, Kipnis J (2014b). T cells in the central nervous system:messengers of destruction or purveyors of protection? Immunology 141:340-344.
269. Wang F, Smith NA, Xu Q, Goldman S, Peng W, Huang JH, et al. (2013a). Photolysis ofcaged Ca2+ but not receptor-mediated Ca2+ signaling triggers astrocyticglutamate release. J Neurosci 33: 17404-17412.
270. Wang ZC, Zhao J, Li S (2013b). Dysregulation of synaptic and extrasynapticN-methyl-D-aspartate receptors induced by amyloid-beta. Neurosci Bull 29:752-760.
271. Wei L, Simen A, Mane S, Kaffman A (2012). Early life stress inhibits expression of anovel innate immune pathway in the developing hippocampus. Neuropsychopharmacology37: 567-580.
272. Wei R, Jonakait GM (1999). Neurotrophins and the anti-inflammatory agentsinterleukin-4 (IL-4), IL-10, IL-11 and transforming growth factor-beta1 (TGFbeta1)down-regulate T cell costimulatory molecules B7 and CD40 on cultured ratmicroglia. J Neuroimmunol 95: 8-18.
273. Whitton AE, Treadway MT, Pizzagalli DA (2015). Reward processing dysfunction inmajor depression, bipolar disorder and schizophrenia. Curr Opin Psychiatry 28:7-12.
274. Wohleb ES, Franklin T, Iwata M, Duman RS (2016). Integrating neuroimmunesystems in the neurobiology of depression. Nat Rev Neurosci 17: 497-511.
275. Wohleb ES, McKim DB, Shea DT, Powell ND, Tarr AJ, Sheridan JF, et al. (2014). Reestablishmentof anxiety in stress-sensitized mice is caused by monocytetrafficking from the spleen to the brain. Biol Psychiatry 75: 970-981.
276. Woodbury-Farina MA (2014). The importance of glia in dealing with stress. PsychiatrClin North Am 37: 679-705.
277. Xie Z, Morgan TE, Rozovsky I, Finch CE (2003). Aging and glial responses tolipopolysaccharide in vitro: greater induction of IL-1 and IL-6, but smaller inductionof neurotoxicity. Exp Neurol 182: 135-141.
278. Yang L, Wang M, Guo YY, Sun T, Li YJ, Yang Q, et al. (2016). Systemic inflammationinduces anxiety disorder through CXCL12/CXCR4 pathway. Brain Behav Immun56: 352-362.
279. Ye ZC, Sontheimer H (1996). Cytokine modulation of glial glutamate uptake: apossible involvement of nitric oxide. Neuroreport 7: 2181-2185.
280. Zamanian JL, Xu L, Foo LC, Nouri N, Zhou L, Giffard RG, et al. (2012). Genomicanalysis of reactive astrogliosis. J Neurosci 32: 6391-6410.
281. Zarate C Jr, Machado-Vieira R, Henter I, Ibrahim L, Diazgranados N, Salvadore G(2010). Glutamatergic modulators: the future of treating mood disorders? HarvRev Psychiatry 18: 293-303.
282. Zeevalk GD, Bernard LP, Sinha C, Ehrhart J, Nicklas WJ (1998). Excitotoxicity andoxidative stress during inhibition of energy metabolism. Dev Neurosci 20:444-453.
283. Zerangue N, Kavanaugh MP (1996). Flux coupling in a neuronal glutamatetransporter. Nature 383: 634-637.
284. Zhou Y, Danbolt NC (2014). Glutamate as a neurotransmitter in the healthy brain. JNeural Transm 121: 799-817.
285. Zink M, Vollmayr B, Gebicke-Haerter PJ, Henn FA (2010). Reduced expression ofglutamate transporters vGluT1, EAAT2 and EAAT4 in learned helpless rats, ananimal model of depression. Neuropharmacology 58: 465-473.
286. Zou JY, Crews FT (2005). TNF alpha potentiates glutamate neurotoxicity by inhibitingglutamate uptake in organotypic brain slice cultures: neuroprotection by NFkappa B inhibition. Brain Res 1034: 11-24.